ADMA Biologics (ADMA) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed ADMA Biologics (ADMA) over the past year, gaining 304.8% versus a loss of 29.7%. Over five years, ADMA leads with a +841.8% price change compared with -58.1% for SYRE. Spyre Therapeutics is the larger company by market cap ($7.91 billion vs $2.32 billion), about 3.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | SYRE |
|---|---|---|
| Share price | $10.36 | $85.69 |
| Market cap | $2.32B | $7.91B |
| 1-day change | +0.29% | +7.25% |
| YTD return | -43.20% | +161.57% |
| 1-year return | -29.72% | +304.77% |
| 5-year return | +841.82% | -58.10% |
| P/E ratio (TTM) | 14.80 | — |
| Forward P/E | 10.98 | — |
| EPS (TTM) | $0.70 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | $0 |
| Revenue growth (YoY) | +19.63% | — |
| Net income (latest FY) | $146.93M | $-155.20M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | — |
| Net margin | 28.80% | — |
| 52-week high | $20.46 | $110.18 |
| 52-week low | $7.21 | $18.12 |
| Distance from 52-week high | -49.36% | -22.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +64.09% | +40.28% |
| Average volume | 2.66M | 1.22M |
| Shares outstanding | 223.98M | 92.29M |
| Employees | 640 | 125 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Spyre Therapeutics is about 3.4 times larger than ADMA Biologics by market value ($7.91B vs $2.32B).
- SYRE has outperformed ADMA by 334.5 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Healthcare · Biotechnology · 640 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Healthcare · Biotechnology · 125 employees
ADMA vs SYRE FAQ
Which is bigger, ADMA Biologics or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $7.91B compared with $2.32B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or SYRE?
SYRE returned +304.77% over the past 12 months, compared with -29.72% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.